Fredun Pharmaceuticals Ltd

Fredun Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Fredun Pharmaceuticals Ltd

₹ 807 -0.82%
04 Jul - close price
fredungroup.com BSE: 539730
About

Incorporated in 1987, Fredun Pharmaceuticals
Ltd manufactures & exports healthcare and pharmaceuticals products[1]

Key Points

Business Overview:[1]
The company, a subsidiary of the Fredun Group, manufactures pharmaceutical and allopathic formulations including tablets, syrups, capsules, and ointments across therapeutic areas like anti-diabetics, anti-retrovirals, and anti-hypertensives. It has also expanded into dietary and herbal supplements, nutraceuticals, diagnostic kits, and animal healthcare products through group entities Fredun Healthcare Pvt. Ltd. and Fredna Enterprises.

Website BSE
  • Market Cap ₹ 381 Cr.
  • Current Price ₹ 807
  • High / Low ₹ 904 / 635
  • Stock P/E 18.3
  • Book Value ₹ 299
  • Dividend Yield 0.09 %
  • ROCE 18.9 %
  • ROE 15.8 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is expected to give good quarter
  • Company has delivered good profit growth of 61.4% CAGR over last 5 years
  • Company's median sales growth is 26.8% of last 10 years

Cons

  • Debtor days have increased from 85.2 to 142 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
71.85 48.42 70.32 77.96 79.81 62.05 81.98 87.00 118.03 78.82 107.35 102.70 167.41
66.46 44.55 63.52 70.66 67.55 54.44 72.37 76.48 106.87 68.34 93.40 89.48 149.97
Operating Profit 5.39 3.87 6.80 7.30 12.26 7.61 9.61 10.52 11.16 10.48 13.95 13.22 17.44
OPM % 7.50% 7.99% 9.67% 9.36% 15.36% 12.26% 11.72% 12.09% 9.46% 13.30% 12.99% 12.87% 10.42%
-0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00
Interest 1.72 1.91 1.86 1.95 3.55 2.61 2.90 3.77 4.37 3.91 5.31 5.00 8.15
Depreciation 0.58 0.65 0.72 0.74 0.70 0.92 0.94 0.99 0.96 1.05 1.06 1.09 1.25
Profit before tax 3.09 1.31 4.22 4.61 8.01 4.08 5.77 5.76 5.83 5.52 7.58 7.13 8.04
Tax % 25.57% 27.48% 25.12% 25.16% 51.44% 41.18% 31.72% 26.74% 13.38% 25.18% 43.54% 25.25% 12.06%
2.30 0.94 3.15 3.46 3.89 2.40 3.94 4.22 5.06 4.13 4.27 5.33 7.07
EPS in Rs 5.19 2.11 7.07 7.66 8.58 5.24 8.41 8.98 10.76 8.75 9.04 11.29 14.97
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
21 25 42 57 60 97 113 134 222 275 348 456
20 24 38 53 54 87 104 126 208 247 310 401
Operating Profit 1 2 4 3 6 10 8 8 14 28 38 55
OPM % 7% 7% 9% 6% 10% 11% 7% 6% 6% 10% 11% 12%
0 0 1 2 0 0 1 1 2 2 1 -0
Interest 1 1 2 2 2 3 4 4 5 9 14 22
Depreciation 1 1 1 1 1 1 2 2 2 3 4 4
Profit before tax 0 1 2 2 3 6 2 3 9 18 21 28
Tax % 47% 52% 42% 36% 34% 28% 24% 37% 26% 38% 27% 26%
0 0 1 1 2 4 2 2 6 11 16 21
EPS in Rs 1.02 1.11 4.55 6.08 5.11 11.18 4.76 5.04 14.30 23.85 33.22 44.07
Dividend Payout % -0% -0% 13% 10% 12% 6% 14% 14% 5% 3% 2% 2%
Compounded Sales Growth
10 Years: 34%
5 Years: 32%
3 Years: 27%
TTM: 31%
Compounded Profit Growth
10 Years: 54%
5 Years: 61%
3 Years: 49%
TTM: 33%
Stock Price CAGR
10 Years: %
5 Years: 34%
3 Years: 0%
1 Year: -5%
Return on Equity
10 Years: 13%
5 Years: 13%
3 Years: 15%
Last Year: 16%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 2 2 2 2 3 4 4 4 4 5 5 5
Reserves 0 0 1 2 19 35 37 39 64 92 117 137
7 9 16 21 10 19 35 40 53 87 106 166
8 11 24 30 47 47 65 79 66 74 81 179
Total Liabilities 18 23 43 56 79 105 141 162 187 257 308 487
7 8 15 16 16 31 31 30 32 39 47 53
CWIP -0 1 -0 4 11 -0 -0 -0 -0 -0 -0 -0
Investments -0 -0 -0 -0 -0 0 0 0 0 0 1 2
11 14 29 36 52 74 110 131 155 218 260 433
Total Assets 18 23 43 56 79 105 141 162 187 257 308 487

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
-1 2 3 4 17 1 -11 0 -2 -14 -0 -29
-2 -3 -6 -7 -8 -5 -1 -1 -4 -9 -8 -6
2 1 3 3 -8 4 14 -1 7 25 6 38
Net Cash Flow -0 0 1 -1 1 0 2 -2 1 1 -2 3

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 59 75 98 131 94 67 126 112 148 46 68 142
Inventory Days 107 102 140 68 170 249 227 242 96 264 246 265
Days Payable 152 167 221 224 360 205 208 215 101 104 88 160
Cash Conversion Cycle 14 11 17 -24 -96 110 145 139 144 205 225 247
Working Capital Days 31 20 16 10 42 99 141 144 144 191 190 202
ROCE % 14% 14% 25% 18% 16% 21% 10% 10% 13% 18% 17% 19%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
51.04% 51.04% 50.34% 50.15% 49.62% 49.31% 49.16% 49.17% 49.17% 48.93% 48.93% 48.93%
1.68% 1.68% 1.66% 1.65% 1.64% 1.60% 1.60% 1.60% 1.60% 1.59% 1.59% 1.59%
47.27% 47.27% 48.00% 48.20% 48.74% 49.08% 49.24% 49.24% 49.23% 49.47% 49.47% 49.47%
No. of Shareholders 3,6903,9014,1384,5214,6256,3136,8377,5077,5118,0188,1217,976

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • Jun 2025
    Transcript
    Notes
    PPT
  • Jun 2025
    Transcript
    Notes
    PPT
  • Feb 2023
    Transcript
    Notes
    PPT
  • Jun 2019
    Transcript
    Notes
    PPT